• Mutation; HGNC; HGNC:3236; EGFR; Simple; p.Leu861Gln (c.2582T>A); ClinVar=VCV000163380; Zygosity=Unspecified (PubMed=31882684).
  

PubMed=31882684; DOI=10.1038/s41598-019-56356-4; PMCID=PMC6934824
Kim S.-Y., Lee J.Y., Kim D.H., Joo H.-S., Yun M.R., Jung D., Yun J., Heo S.G., Ahn B.-C., Park C.W., Pyo K.H., Chun Y.J., Hong M.H., Kim H.R., Cho B.C.
Patient-derived cells to guide targeted therapy for advanced lung adenocarcinoma.
Sci. Rep. 9:19909.1-19909.12(2019)

PubMed=39874964; DOI=10.1016/j.xcrm.2025.101929
Oh S.Y., Park S., Lee S., Lee E.J., Kim T.H., Choi S.-J., Park S.Y., Kim J.H., Lim S.M., Lee J.B., Cho B.C., Hong M.H., Yun M.R.
The potential of lazertinib and amivantamab combination therapy as a treatment strategy for uncommon EGFR-mutated NSCLC.
Cell Rep. Med. 6:101929.1-101929.12(2025)